Please login to the form below

Not currently logged in

Bispecific antibody

This page shows the latest Bispecific antibody news and features for those working in and with pharma, biotech and healthcare.

Merck expands partnership with Zymeworks for multispecific antibodies

Merck expands partnership with Zymeworks for multispecific antibodies

Zymeworks’ lead candidate, a bispecific antibody engineered using its Azymetric technology Zanidatamab, is currently in phase 2 clinical development. ... Its second clinical candidate, a bispecific antibody drug conjugate, ZW49, is in phase 1 clinical

Latest news

More from news
Approximately 4 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    In April last year, it achieved a very successful IPO on the US Nasdaq, generating $208m thanks to investor belief in its cancer-focused antibody-based pipeline. ... In addition to traditional antibodies, the pipeline also includes antibody drug

  • Deal Watch December 2016 Deal Watch December 2016

    5, 500. Merus Labs (Canada). Incyte (US). Discovery collaboration. Biclonics bispecific antibody technology for up to 11 research programmes, including 2 in immuno-oncology. ... Not disclosed. Bispecific antibody technology. Exicure. Purdue. $790m. Not

  • Deal Watch September 2016 Deal Watch September 2016

    The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... Pfizer acquired an exclusive licence to OncoImmune's

  • Deal Watch August 2016 Deal Watch August 2016

    469. Genmab (DK). Gilead (US). Licence. DuoBody technology platform to develop bispecific antibody candidates for targeting HIV plus option to second licence.

  • Deal Watch June 2016 Deal Watch June 2016

    These antibody molecules comprise the XmAb Bispecific Fc domain as a scaffold for the two antigen binding domains. ... Tiered low double digit. Worldwide exclusive rights to bispecific technology for four Novartis target pairs.

More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.

Latest appointments

  • New hires at Crescendo, Healx and Galecto New hires at Crescendo, Healx and Galecto

    late phase clinical trials. Before that, he was clinical research physician at Chugai Pharma Europe, where he led clinical development for a bispecific T-cell engaging antibody programme and other early

  • New hires at FibroGen, Saniona and Turbine New hires at FibroGen, Saniona and Turbine

    Previously, she held the position of senior vice president of drug discovery at F-star, overseeing all internal and collaborative bispecific antibody discovery programmes.

  • F-star hires ex-BMS immuno-oncology leader

    Dr Kayitalire’s background will be of benefit to F-star, as it looks to advance its bispecific antibody pipeline in oncology. ... Hewill oversee the clinical development of F-star’s lead product candidate, FS118, a LAG-3/PD-L1-targeting tetravalent

  • F-star appoints GSK's Neil Brewis F-star appoints GSK's Neil Brewis

    Cambridge-based antibody research company F-Star has appointed Dr Neil Brewis as chief scientific officer. . ... This appointment strengthens our experienced management team and supports F-star's strategy to lead the bispecific antibody space in

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...